Barclays’s Evoke Pharma EVOK Stock Holding History

Barclays’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-3	Closed	-$2K	–	7352
2014 Q3	$2K	Buy	+3	New	+$2.9K	﹤0.01%	7394

Other funds holding EVOK

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays's EVOK Position: Q4 2014 in Review

Barclays sold out of Evoke Pharma (EVOK) in Q4 2014, closing a stake of 3 shares — an estimated $2K sold.

Barclays first reported a position in EVOK in Q3 2014 and held it in 1 quarter. The position peaked at $2K in Q3 2014. 11 funds tracked by Wall St. Rank hold EVOK as of Q4 2014.

Barclays reported no remaining Evoke Pharma position as of Q4 2014 after selling out during the quarter.
Barclays sold 3 Evoke Pharma shares in Q4 2014, an estimated $2K.
Barclays first reported a position in Evoke Pharma in Q3 2014 and held it in 1 quarter.
Barclays's Evoke Pharma position peaked at $2K in Q3 2014.
11 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2014.

Based on Barclays's 13F filing for Q4 2014, filed 13 Feb 2015.